Navigation Links
Study by Ocala Oncology/The US Oncology Network Shows Use of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Improves Overall Survival
Date:9/28/2011

OCALA, Fla. and THE WOODLANDS, Texas, Sept. 28, 2011 /PRNewswire/ -- Thomas Cartwright, M.D., medical oncologist with Ocala Oncology and a member of the Pharmacy & Therapeutics (P&T) Committee and Pathways Task Force Committee, physician advisory groups within The US Oncology Network, presented findings from a study titled "Survival outcomes with use of bevacizumab beyond progression (BBP) in metastatic colorectal cancer (MCRC) patients (Pts)" at 9:30am on September 25 during the "Gastrointestinal Malignancies - Colorectal Cancer" Poster Session at the 2011 European Multidisciplinary Cancer Congress (EMCC) taking place in Stockholm, Sweden.

(Logo:  http://photos.prnewswire.com/prnh/20110916/MM70140LOGO)

"The data for the study, derived from the patient information entered by providers into McKesson Specialty Health's EHR, iKnowMed™, shows that patients with metastatic colorectal cancer, treated in a community setting with bevacizumab beyond progression, experienced improved overall survival," said Dr. Cartwright. "These findings are consistent with similar studies, such as BRiTE and ARIES, which are two large registry trials showing extended survival with similar results."

Dr. Cartwright led the study for The US Oncology Network, one of the nation's largest networks of community-based oncology physicians dedicated to advancing cancer care in America. This study involved medical oncologists from across the country and evaluated data from as far back as 2004 using McKesson Specialty Health's electronic health record (EHR) system, iKnowMed. iKnowMed contains more than 975,000 patient records and is used by nearly 1,000 independent providers in community-based cancer care settings across the United States. iKnowMed has also been the EHR of choice for affiliates of The US Oncology Network.

Dr. Cartwright's abstract, 6.150, can be found in the program and abstract book (available on USB at the Congress) and online at www.ecco-org.eu. The European Multidisciplinary Cancer Congresses are the only multidisciplinary and multi-professional educational opportunities in oncology to take place in Europe.

About Ocala Oncology

Ocala Oncology is a six-physician private practice in Ocala, Florida that provides patients with state-of-the-art, comprehensive care for a wide range of cancers and hematological disorders. Ocala Oncology provides patients access to new treatments and offers a brighter future through clinical research and advanced therapies. With offices in Ocala (352) 732-4032 and The Villages (352) 259-8940, Ocala Oncology provides this advanced treatment in the comfort of warm personal centers in the patient's own community.

Ocala Oncology is united in healing with The US Oncology Network, one of the nation's largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Ocala Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. Ocala Oncology participates in clinical trials through US Oncology Research, which has helped to develop 43 FDA approved cancer therapies. For more information, visit www.ocalaoncology.com or www.usoncology.com.

About McKesson Specialty Health

McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.

About The European Multidisciplinary Cancer Congress

The European Multidisciplinary Cancer Congresses brings together the 16th ECCO, 36th European Society for Medical Oncology (ESMO), and the 30th European Society for Therapeutic Radiotherapy & Oncology (ESTRO) Congresses to form an organized partnership with ECCO founding members European Society of Surgical Oncology (ESSO), European Association for Cancer Research (EACR), European Oncology Nursing Society (EONS) and the European Society for Pediatric Oncology (SIOPE).

The 2011 EMCC integrates basic and translational science, surgery, radiotherapy, medical oncology, advocacy and care into one multidisciplinary mass gathering and celebration of European basic, translational and clinical studies. The first jointly organized multidisciplinary Cancer Congress, ECCO 15/ESMO 34, took place in Berlin, Sept. 21 - 24 2009, and marked a milestone in advancing cancer research and treatment across Europe by drawing a record multi-stakeholder audience of nearly 15,000 participants, and presenting more cutting-edge and late breaking data than ever before.


'/>"/>
SOURCE The US Oncology Network
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
2. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
3. To Succeed in Crowded Market, Diabetes Manufacturers Beginning Key Launch Tactics Earlier, Study Says
4. Swype Cold & Flu Shield Significantly Reduces Occurrence of Colds in Clinical Study
5. Biodel Reports Top-Line Results From Pump Study of Experimental Insulins
6. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
7. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
8. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
9. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
10. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
11. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):